Lifileucel, a one-time autologous TIL cell therapy, achieved a 31.4% objective response rate (ORR) with a median duration of response (DOR) not reached at a median of 36.5 months of follow-up, in patients with advanced (unresectable or metastatic) melanoma who progressed after ICI and ...
The inflammatory responses from synovial fibroblasts and macrophages and the mitochondrial dysfunction in chondrocytes lead to oxidative stress, disrupt extracellular matrix (ECM) homeostasis, and accelerate the deterioration process of articular cartilage in osteoarthritis (OA). In recent years, it has been...
LONG-TERM EFFICACY AND PATTERNS OF RESPONSE OF LIFILEUCEL TUMOR- INFILTRATING LYMPHOCYTE (TIL) CELL THERAPY IN PATIENTS WITH ADVANCED MELANOMA: A 4-YEAR ANALYSIS OF THE C-144-01 STUDY Theresa Medina,1 Jason A. Chesney,2 Eric Whitman,3 Harriet Kluger,4 Sajeve Thomas,5 Amod Sarnaik,6 John...
In preclinical models of immunologically cold melanoma, low-dose whole-brain radiation therapy (LD-WBRT) at 4 Gy in a single fraction significantly reduced intracranial tumors and improved survival rates. Conversely, a high-dose radiation-based in-situ vaccination (ISV) regimen, incorporating 12 Gy ...
Efficacy and safety of adult human bone marrow-derived, cultured, pooled, allogeneic mesenchymal stromal cells (Stempeucel(R)): preclinical and clinical trial in osteoarthritis of the knee joint. Arthritis Res Ther. 2016;18(1):301. https://doi.org/10.1186/s13075-016-1195-7. Article Pub...
Safety and efficacy of cryopreserved autologous tumor infiltrating lymphocyte therapy (LN-144, lifileucel) in advanced metastatic melanoma patients who progressed on multiple prior therapies including anti-PD-1 J Clin Oncol, 37 (Suppl 15) (2019), p. 2518 2518 Google Scholar 54. T. Borch, R....
Notably, 56.3% of responders to lifileucel had LDH levels at or below the ULN, and 62.5% had over 3 baseline target and nontarget lesions. The median sum of diameter for target lesions for responders was 68.8 mm (range, 13.5-552.9). The safety profile of lifileucel was consistent with...
During a Targeted Oncology™ Case-Based Roundtable™ event, Michael B. Atkins, MD, discussed with other oncologists what efficacy and safety data aid them in choosing an immunotherapy regimen for patients with metastatic melanoma. This is the first of 2 articles based on this event. ...
This study evaluates lifileucel combined with anti-PD-1 therapy in front-line advanced melanoma.Methods:IOV-COM-202 (NCT03645928) Cohort 1A assesses the efficacy and safety of lifileucel and pembrolizumab (pembro) in pts with ICI-naive unresectable or metastatic melanoma. Pts may have received ...
Darovasertib and crizotinib demonstrated promising efficacy and tolerable safety in patients with metastatic uveal melanoma, according to preliminary results of a phase 1/2 trial announced in a press release from IDEAYA Biosciences.